The EML4-ALK fusion variant 1 (E13; A20) in CCL-185IG has been extensively validated on both the genomic level and transcript level by sequencing. In addition, the expression of EML4-ALK fusion protein was verified by the Western blot method. This isogenic line has been shown to be more sensitive to ALK inhibitor, Crizotinib, when compared to its parental cell line (ATCC® CCL-185 ™) in cell-based assays.
|Date Created||01/18/2016 10:20 AM
|Date Updated||01/18/2016 10:21 AM